Gsa Capital Partners LLP Poseida Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

  • $1.32 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$1.66 - $3.4 $34,264 - $70,179
20,641 Added 38.65%
74,040 $130,000
Q1 2023

May 12, 2023
SELL
$3.08 - $8.73 $129,575 - $367,271
-42,070 Reduced 44.07%
53,399 $164,000
Q4 2022

Feb 13, 2023
BUY
$3.33 - $6.38 $317,911 - $609,092
95,469 New
95,469 $506,000
Q1 2022

May 11, 2022
SELL
$3.22 - $7.04 $272,737 - $596,295
-84,701 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$6.23 - $7.6 $527,687 - $643,727
84,701 New
84,701 $577,000

Others Institutions Holding PSTX

# of Institutions
98
Shares Held
38.5M
Call Options Held
377K
Put Options Held
22.2K
View Full List

About Poseida Therapeutics, Inc.

PSTX Quotes by TradingView
  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $810M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email